Theralase’s Innovative Anti-Cancer Technology Validated at Major International Conferences

Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at two major international scientific conferences. Acceptance at these conferences validates the significance of the technology and its efficacy in the destruction of cancer cells in research performed by Theralase's internationally acclaimed scientists.

The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER World of Photonics conference in Munich, Germany on May 15, 2013.

The effective destruction of bacteria using Theralase’s light activated Photo Dynamic Compound technology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.

In further developments, Theralase’s Chief Scientific Officer, Dr. Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, which publishes clinical and scientific studies concerned with the clinical and scientific application of lasers and biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured the clinical success of Theralase’s pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy Applications for Osteoarthritis and Chronic Joint Pain.”

Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase’s scientific and clinical research has been recognized and acclaimed by two of the finest international scientific conferences and has been published in a peer reviewed medical journal. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenue increases for the Company. To accelerate this process, we are actively looking to collaborate with strategic partners to further develop our technologies and increase shareholder value. Theralase’s strong PDC pipeline has scientifically proven that our PDC technology is capable of consistently producing cell kill levels of 100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly more effective in destroying cancer cells and bacteria than currently FDA approved Photo Dynamic Compounds.”

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

 

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White                                                                     

President & CEO                    

416-699-LASE (5273) ext. 225                                   

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-699-LASE (5273) ext. 224

khachey@theralase.com 

Arkady Mandel

Chief Scientific Officer

416-699-LASE (5273) ext. 260

amandel@theralase.com

Greg Bewsh

Director of Investor Relations

416-699-LASE (5273) ext. 258

gbewsh@theralase.com   

Theralase Photo Dynamic Compounds Effective in Destruction of Drug Resistant Bacteria

Toronto, Ontario – October 17, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its Photo Dynamic Compound (PDC) technology has been proven effective in the destruction of  staphylococcus aureus and its multi drug resistant strain, methicillin resistant staphylococcus aureus, also known as MRSA.

MRSA is a bacteria strain that has grown resistant to antibiotics and hence has the potential of causing invasive infections, which are extremely difficult to treat in 25% of the population infected. In 2005, the Centers for Disease Control and Prevention reported that 94,000 individuals were hospitalized as a result of MRSA infections and there were 18,650 deaths as a result, costing the US healthcare system an additional $45 billion a year.

The scientific data supporting this discovery was presented yesterday at the 9^th International Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in Brixen, Italy. The presentation by Dr. Lothar Lilge confirms the significance of the research conducted by Theralase’s and University Health Network’s (UHN) scientists.

Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, “Theralase unveiled to the scientific community its advanced sterilization platform technology that is able to deliver an 8 log or 99.999999% kill rate, which is comparable with complete sterilization of life threatening infectious microorganisms, such as staphylococcus aureus and MRSA.  Theralase’s new PDC technology would therefore be well suited to preventing hospital acquired infections, as well as infections found in nursing homes, schools or bacterial contaminations in food processing facilities. Quite simply, once MRSA bacteria have been detected, they could be quickly destroyed utilizing Theralase’s patented Photo Dynamic Compounds and proprietary light sources.”

Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre, UHN stated, “Theralase’s PDCs in conjunction with light exposure were shown to achieve essentially complete sterilization, even at low concentrations, against staphylococcus aureus and MRSA in an in vitro laboratory setting. The effective dose of tested PDCs was not toxic for human tissues even after 4 hours of incubation demonstrating their suitability and safety to sterilization applications. As an added benefit, the Theralase PDCs maintained their sterilizing activity even in low oxygen conditions demonstrating a Type I photosensitization effect that may open up new opportunities for the safe and effective destruction of many strains of deadly organisms and tumours that thrive in low oxygen environments, such as cancer.”

Dr. Arkady Mandel went on to say, “The dramatic increase of antibiotic resistance in bacteria has led me to investigate whether Theralase’s PDCs would be effective in the destruction of MRSA, as an alternative to antibacterial pharmaceutical drugs. Our successes to date will allow Theralase’s PDCs to be used in the future to combat difficult to heal invasive infections. The Theralase PDCs in these studies have been chosen for their low dark toxicity to human tissue and for their high cancer and bacteria targeting properties. The Theralase PDCs are extremely promising for the development of advanced disinfection and sterilization strategies for controlling and eliminating hospital and community acquired infections, such as MRSA.”

Roger Dumoulin-White, President and CEO of Theralase stated, “Based on our recent successes with our PDC technology in destroying MRSA, Theralase is actively pursuing early commercialization of this technology through strategic partnerships to co-develop the technology for particular sterilization applications. As an added benefit, due to the very low concentrations of PDCs required for sterilization, the costs of administering this technology will be very cost effective. The early commercialization of our patented PDC technology with strategic partners will dramatically improve the financial revenues of the organization. These scientific studies thus highlight Theralase’s commitment to advancing its exclusive patented technologies for the ultimate goal of greater commercial opportunities for the Company.”

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.  

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & Chief Executive Officer

416-447-8455 ext. 225

rwhite@theralase.com                

Why Invest in Theralase?

• Proven clinical technology (TLC-1000)
• Commercial therapeutic laser business and brand developed over last 18 years
• No debt
• Positive cash flow / double digit growth
• Competitive technical advantage (Activates 3 cellular pathways: iNOS, ATP, Na+ / K+)
• Effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing
• Theralase therapeutic laser system has now been proven clinically effective in the relief of chronic knee pain and for the treatment of osteoarthritis
• Photo Dynamic Compound (PDC) cancer destruction in animals helps pave the way for human trials
• Successful pre-clinical trials - total destruction of cancers and bacteria (including MRSA)
• Large addressable US market ($ billions)
• Future technology (Patented biofeedback technology and patented PDC cancer destruction)
• Opportunity for growth (revenue, profit)
• IP protection (multiple issued patents)
• Experienced management team (20+ years)
• Clear vision and execution strategy
• Listed on the TSX Venture Exchange (TLT:V)

For more information please visit www.theralase.com or call 1-866-843-5273 

Theralase Cancer Therapy and Bacterial Destruction Technologies Presented at Major International Conferences

Toronto, Ontario -- April 26, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative research on Photo Dynamic Compound (PDC) destruction of bacteria, cancer cells and solid subcutaneous (under the skin) animal tumours was recently presented at two major international scientific conferences, demonstrating the significance and validity of the research performed by Theralase’s world renowned and internationally acclaimed scientists.

On January 23, 2012 in San Francisco, California at the BiOS SPIE Photonics West Conference (the largest photonics conference in the world) Theralase presented scientific research supporting a new cost effective methodology to quickly quantify E. coli and Listeria bacteria.  This new technology would be indispensable for food manufacturing and handling facilities, restaurants, schools, nursing homes, hospitals or any organization concerned with the early detection of bacterial concentrations in food. Once these microorganisms have been quantified with this new technology, they could be quickly destroyed utilizing Theralase’s patented Photo Dynamic Compounds (PDCs) and proprietary light sources. A very simple solution that could prove invaluable to an industry plagued with food recalls that at recent estimates cost the industry over $157 billion a year in North America alone and loss of life.

On April 19, 2012 in Brussels, Belgium at the Photonic Solutions for Better Health Care (a division of Photonics Europe), Theralase presented new scientific data supporting the application of Theralase’s anti-cancer PDCs to target and effectively destroy a variety of cancer cells. The PDCs have also shown remarkable success in the complete destruction of highly aggressive tumours in preclinical, subcutaneous (under the skin) cancers in mice.

At the same conference, Theralase also unveiled to the scientific community its advanced sterilization platform technology that enables a 100% kill of life threatening infectious microorganisms, such as staphylococcus aureus also known as "golden staph”.  

Staphylococcus aureus (S. aureus) is the most potent of the many staphylococcal species in existence and is a leading cause of illness and death in humans despite the availability of numerous antibiotics. Each year, more than 500,000 patients in American hospitals contract a staphylococcal infection leading to 99,000 preventable deaths and adding an additional $35 to $45 billion in costs annually to the US healthcare system. (Source: Centers for Disease Control and Prevention).

“Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds (PDC) in the areas of anti-cancer and anti-bacterial applications.  This focus is being used to develop a library of first-in-class light activated compounds through various cancer and bacterial models, which are proving to be more effective in low oxygen environments, preferentially preferred by cancer cells and a number of different types of bacteria. Theralase is on the path to substantial growth and the early commercialization of our patented PDC technology in these fields, should facilitate exponential revenue increase.” said Roger Dumoulin-White, President and CEO of Theralase. He added, “Our strong PDC pipeline, one of the most innovative in the industry, has scientifically proven that our PDC technology is capable of consistently producing 100% kill levels across a wide range of bacteria and provides highly effective tumour destruction in a mouse model.  I am very proud of our scientific team and pleased that their work was recognized and acknowledged by two of the finest international academic assemblies worldwide; specifically: BiOS SPIE Photonics West and Photonics Europe.”

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.  

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Theralase and George Brown College Join in Government-Funded Research to Combat Food Contamination - TV Coverage

Theralase Technologies Inc. (TSXV:TLT) has partnered with George Brown College’s Centre for Hospitality and Culinary Arts to conduct applied research in the use of patented photodynamic compounds (PDCs) activated by its proprietary laser technology to destroy microbial pathogens associated with food contamination. See the news story on CTV at http://watch.ctv.ca/news/health/lifetime-with-pauline-chan/#clip489318

The results of the study are expected in September 2011 and will be followed by further lab testing and a pilot project at a commercial food processing facility.

For further information please contact:

 Greg Bewsh

Director of Investor Relations

416-447-8455 ext. 262

gbewsh@theralase.com 

www.theralase.com